{ "model": { "rank": 5840, "code": "thing-q205214", "model_id": "vr.tr.guillain-barr-syndrome", "name": "Guillain–Barré syndrome", "purpose": "Enable an AI agent to represent Guillain-Barré syndrome, assess evidence and episode severity, and identify appropriate clinical review, escalation and follow-up actions.", "family": "Thing Registry", "category": "Information and virtual systems", "status": "research-draft", "kind": "thing", "plane": "INF", "domain": "INF.KNW", "industry": "", "version": "", "url": "/models/thing/q205214/", "tier": 2, "score": 64, "payload": { "layer": "wikidata", "aliases": [ "acute motor axonal neuropathy", "acute motor and sensory axonal neuropathy", "variant of Guillain-Barre syndrome" ], "aliasCount": 3, "merged": 3, "knownIn": 64, "facets": null, "markers": [], "lexicalClass": "", "senseRank": null, "alsoRegisteredAs": null, "source": { "dataset": "wikidata", "item": "Q205214", "url": "https://www.wikidata.org/wiki/Q205214", "license": "CC0 1.0" } }, "research": { "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-07T09:35:33Z", "providers": [ "Codex", "Grok" ], "missingProviders": [], "pass": 2, "cost": { "grok": { "usd": 0.00266832, "turns": 1, "seconds": 40.9, "error": null }, "codex": { "seconds": 123.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.3\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a07b37-3535-7d72-8755-742b0a299f72\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: Guillain-Barré syndrome\nRegistry id: vr.tr.guillain-barr-syndrome\nPlane / domain: INF / INF.KNW\nRegistry definition: (none recorded)\nNames folded int" } } }, "metaModel": { "id": "THING-Q205214", "registryId": "vr.tr.guillain-barr-syndrome", "name": "Guillain–Barré syndrome", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "INF.KNW" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q205214/", "model": { "registry_id": "vr.tr.guillain-barr-syndrome", "name": "Guillain–Barré syndrome", "purpose": "Enable an AI agent to represent Guillain-Barré syndrome, assess evidence and episode severity, and identify appropriate clinical review, escalation and follow-up actions.", "definition": "Guillain-Barré syndrome is an acute, typically post-infectious, immune-mediated polyradiculoneuropathy in which molecular mimicry against peripheral-nerve myelin or axonal membranes produces rapidly progressive, usually symmetrical flaccid weakness, areflexia, and often albuminocytologic dissociation in cerebrospinal fluid.", "scope_statement": "This INF.KNW model owns the recognition criteria, phenotype distinctions, episode states, evidence requirements and clinical decision dependencies of Guillain-Barré syndrome under vr.tr.guillain-barr-syndrome; individual patients, investigations and treatments are linked entities.", "in_scope": [ "Clinical recognition and diagnostic uncertainty in suspected Guillain-Barré syndrome", "Clinical variants and electrophysiological classifications without creating additional registry entries", "Episode chronology, progression, nadir, stabilization and recovery", "Respiratory, bulbar, autonomic and functional severity", "Dependencies for treatment decisions, reassessment and rehabilitation" ], "out_of_scope": [ "The patient's complete medical record and unrelated conditions", "Independent models of chronic inflammatory demyelinating polyradiculoneuropathy and other diagnostic alternatives", "Laboratory equipment, assay operation and electrophysiology device specifications", "Drug manufacture, prescribing infrastructure and plasma-exchange procedure execution", "Population infection surveillance and vaccine safety causality assessment" ], "distinguishing_features": [ "Assess rapidly progressive, relatively symmetric weakness with reduced tendon reflexes against chronic neuropathy; typical progression reaches nadir within four weeks, with variant exceptions requiring explicit interpretation. [EAN/PNS guideline](https://onlinelibrary.wiley.com/doi/10.1111/jns.12594)", "Check peripheral localization against spinal cord disease: a sensory level or upper motor neuron signs should prompt investigation of an alternative explanation. [EAN/PNS guideline](https://onlinelibrary.wiley.com/doi/10.1111/jns.12594)", "Use cerebrospinal fluid protein and cell count together with nerve-conduction findings as supporting evidence; normal early results do not exclude GBS. [EAN/PNS guideline](https://onlinelibrary.wiley.com/doi/10.1111/jns.12594)", "Distinguish Miller Fisher presentations through ophthalmoplegia, ataxia and reduced reflexes, with anti-GQ1b testing where appropriate, rather than requiring the typical limb-weakness pattern. [EAN/PNS guideline](https://onlinelibrary.wiley.com/doi/10.1111/jns.12594)", "Reconsider acute-onset CIDP when progression continues beyond eight weeks; record the chronology rather than automatically relabeling every deterioration. [EAN/PNS guideline](https://onlinelibrary.wiley.com/doi/10.1111/jns.12594)" ], "characteristics": [ { "name": "Diagnostic standing", "kind": "state", "unit_or_values": "suspected | clinician-supported | uncertain | alternative favored; named criteria and assessment date", "why_it_matters": "Separates working recognition from a settled clinical assessment." }, { "name": "Time from weakness onset", "kind": "measurement", "unit_or_values": "days; onset date or estimated interval", "why_it_matters": "Anchors progression, investigation timing and treatment review." }, { "name": "Clinical phenotype", "kind": "category", "unit_or_values": "motor-sensory | pure motor | Miller Fisher | other named variant | overlap | unclassified", "why_it_matters": "Prevents typical presentation criteria from excluding a variant without review." }, { "name": "Electrophysiological classification", "kind": "category", "unit_or_values": "demyelinating | axonal motor | axonal motor-sensory | equivocal | normal | not tested; criteria and study date", "why_it_matters": "Keeps physiological interpretation distinct from clinical phenotype." }, { "name": "Episode phase", "kind": "state", "unit_or_values": "progressing | plateau | recovering | deteriorating after stabilization | unresolved", "why_it_matters": "Makes changes in trajectory visible." }, { "name": "Muscle strength", "kind": "measurement", "unit_or_values": "MRC grades 0-5 by examined muscle; sum score 0-60 when the specified examination is complete", "why_it_matters": "Supports comparable serial assessment while retaining asymmetry and missing observations." }, { "name": "Functional disability", "kind": "measurement", "unit_or_values": "GBS disability scale 0-6 with version, component description and assessment date", "why_it_matters": "Connects impairment to walking, support needs and longitudinal outcome." }, { "name": "Respiratory reserve", "kind": "measurement", "unit_or_values": "vital capacity in L and mL/kg; respiratory pressures in cm H2O; timestamp, method and reliability", "why_it_matters": "Allows respiratory trends to inform urgent clinical review." }, { "name": "Bulbar and autonomic involvement", "kind": "state", "unit_or_values": "swallowing, cough and secretion handling; blood-pressure instability, rhythm disturbance and bowel/bladder dysfunction; present | absent | unknown", "why_it_matters": "Captures threats that a limb-strength score does not describe." }, { "name": "Antecedent event", "kind": "relation", "unit_or_values": "linked infection or other exposure; event date, evidence and attribution status", "why_it_matters": "Preserves relevant context without treating temporal proximity as established causation." }, { "name": "Disease-directed treatment exposure", "kind": "relation", "unit_or_values": "linked IVIg or plasma-exchange course; indication, dates, completion and adverse events", "why_it_matters": "Makes subsequent response interpretable against actual treatment." } ], "affordances": [ "Organize a suspected episode against named diagnostic criteria and identify missing or contradictory evidence.", "Compare serial examinations and measurements to flag deterioration for clinician review.", "Prepare a respiratory, swallowing and autonomic risk handover with observation times and uncertainties.", "Surface guideline-linked treatment considerations for the responsible clinician using onset, function and prior treatment.", "Track recovery and prompt reassessment when the course no longer fits the working diagnosis.", "Link residual deficits to rehabilitation goals and reassessment dates." ] }, "sources": [ { "id": "who-gbs", "title": "Guillain-Barré syndrome fact sheet", "url": "https://www.who.int/news-room/fact-sheets/detail/guillain-barr%C3%A9-syndrome", "what_it_supports": "", "url_status": "live" } ], "structure": { "bundles": [ { "id": "syndrome-recognition", "name": "Syndrome recognition", "description": "Represent why an episode is considered GBS and where that interpretation remains vulnerable.", "rationale": "Recognition must combine chronology, examination and phenotype without treating any isolated feature as decisive.", "layers": [ { "id": "onset-and-pattern", "name": "Onset and pattern", "description": "Capture the neurological pattern and its development.", "findings": [ { "id": "weakness-reflex-trajectory", "name": "Weakness and reflex trajectory", "description": "Record the distribution, symmetry and evolution of weakness alongside reflex examinations.", "questions": [ { "text": "When did neurological symptoms and objective weakness begin, and how certain are those dates?", "kind": "provenance", "id": "weakness-reflex-trajectory-q01" }, { "text": "Which limbs and cranial functions are affected, and what reflex findings were recorded at each examination?", "kind": "measurement", "id": "weakness-reflex-trajectory-q02" }, { "text": "Does the observed progression fit the diagnostic framework being applied?", "kind": "boundary", "id": "weakness-reflex-trajectory-q03" } ] } ] }, { "id": "phenotype-and-alternatives", "name": "Phenotype and alternatives", "description": "Separate variant recognition from evidence for competing diagnoses.", "findings": [ { "id": "variant-assignment", "name": "Variant assignment", "description": "Record the proposed clinical phenotype and the observations supporting it.", "questions": [ { "text": "Which clinical phenotype best describes the episode, including ophthalmoplegia, ataxia or regional weakness?", "kind": "definition", "id": "variant-assignment-q01" }, { "text": "Which expected features are absent, unexamined or inconsistent with that assignment?", "kind": "boundary", "id": "variant-assignment-q02" } ] }, { "id": "competing-localizations", "name": "Competing localizations", "description": "Keep clinically consequential alternatives and their discriminating evidence explicit.", "questions": [ { "text": "What evidence favors spinal cord disease, neuromuscular junction disease, myopathy or another neuropathy?", "kind": "boundary", "id": "competing-localizations-q01" }, { "text": "Which unresolved alternative requires urgent investigation or specialist review?", "kind": "action", "id": "competing-localizations-q02" } ] } ] } ] }, { "id": "diagnostic-evidence", "name": "Diagnostic evidence", "description": "Make diagnostic support traceable to actual investigations and their timing.", "rationale": "An agent must distinguish missing evidence, early nondiagnostic results and evidence against GBS.", "layers": [ { "id": "timed-investigations", "name": "Timed investigations", "description": "Preserve results together with illness day and interpretive limitations.", "findings": [ { "id": "csf-interpretation", "name": "CSF interpretation", "description": "Represent protein and cell-count results as separate observations.", "questions": [ { "text": "What were CSF protein and white-cell count, with units, reference ranges and day from onset?", "kind": "measurement", "id": "csf-interpretation-q01" }, { "text": "How did the clinician interpret these results, including possible alternative explanations?", "kind": "provenance", "id": "csf-interpretation-q02" } ] }, { "id": "electrodiagnostic-interpretation", "name": "Electrodiagnostic interpretation", "description": "Retain study findings, classification criteria and revisions across serial studies.", "questions": [ { "text": "Which nerves and parameters were examined, and what classification did the report support?", "kind": "measurement", "id": "electrodiagnostic-interpretation-q01" }, { "text": "Is the study sufficiently informative, or has the clinician requested repeat testing?", "kind": "action", "id": "electrodiagnostic-interpretation-q02" } ] } ] }, { "id": "certainty-and-context", "name": "Certainty and context", "description": "Connect the diagnostic conclusion to its framework and supporting history.", "findings": [ { "id": "criteria-based-assessment", "name": "Criteria-based assessment", "description": "Keep clinical judgment and formal case-definition classification separately attributable.", "questions": [ { "text": "Which criteria and version were applied, and which elements are satisfied, missing or contradicted?", "kind": "definition", "id": "criteria-based-assessment-q01" }, { "text": "Who made the diagnostic assessment, when, and from which examination and investigation reports?", "kind": "provenance", "id": "criteria-based-assessment-q02" } ] }, { "id": "antecedent-and-targeted-evidence", "name": "Antecedent and targeted evidence", "description": "Record preceding illness and selectively requested tests without assigning unsupported causation.", "questions": [ { "text": "Which antecedent infections or exposures are documented, and by history or testing?", "kind": "provenance", "id": "antecedent-and-targeted-evidence-q01" }, { "text": "What diagnostic uncertainty would antibody testing, imaging or another targeted investigation resolve?", "kind": "action", "id": "antecedent-and-targeted-evidence-q02" } ] } ] } ] }, { "id": "acute-threat-and-severity", "name": "Acute threat and severity", "description": "Represent physiological danger alongside motor disability.", "rationale": "Weakness can affect breathing and swallowing, while autonomic disturbance can threaten circulation. [NINDS overview](https://www.ninds.nih.gov/health-information/disorders/guillain-barre-syndrome)", "layers": [ { "id": "breathing-and-airway", "name": "Breathing and airway", "description": "Track ventilatory reserve and airway protection as related but distinct concerns.", "findings": [ { "id": "respiratory-trend", "name": "Respiratory trend", "description": "Combine serial respiratory measurements with observed effort and current support.", "questions": [ { "text": "How are vital capacity, respiratory pressures and breathing effort changing, and are measurements reliable?", "kind": "measurement", "id": "respiratory-trend-q01" }, { "text": "Which clinician-approved escalation criteria are met, and has the responsible team been notified?", "kind": "action", "id": "respiratory-trend-q02" } ] }, { "id": "airway-protection", "name": "Airway protection", "description": "Record swallowing, cough and secretion management independently of walking ability.", "questions": [ { "text": "What assessment establishes current swallowing safety, cough effectiveness and secretion handling?", "kind": "measurement", "id": "airway-protection-q01" }, { "text": "What airway, nutrition or swallowing review is required by the documented findings?", "kind": "action", "id": "airway-protection-q02" } ] } ] }, { "id": "autonomic-and-motor-burden", "name": "Autonomic and motor burden", "description": "Represent cardiovascular instability and functional loss without collapsing them into one score.", "findings": [ { "id": "autonomic-instability", "name": "Autonomic instability", "description": "Capture autonomic events, their timing and alternative explanations.", "questions": [ { "text": "Which rhythm disturbances, blood-pressure changes or bowel/bladder abnormalities have been observed?", "kind": "measurement", "id": "autonomic-instability-q01" }, { "text": "What monitoring or escalation plan addresses these events, and which competing causes remain under review?", "kind": "action", "id": "autonomic-instability-q02" } ] }, { "id": "motor-disability-trend", "name": "Motor disability trend", "description": "Track strength and practical function using comparable assessments.", "questions": [ { "text": "What are the current muscle grades, GBS disability grade and actual walking or transfer abilities?", "kind": "measurement", "id": "motor-disability-trend-q01" }, { "text": "Which changes reflect neurological deterioration rather than pain, sedation or another limitation?", "kind": "boundary", "id": "motor-disability-trend-q02" } ] } ] } ] }, { "id": "treatment-decision-and-response", "name": "Treatment decision and response", "description": "Link clinical state to disease-directed treatment review and subsequent observations.", "rationale": "IVIg or plasma exchange decisions depend on timing and severity; corticosteroids are not recommended as GBS-directed treatment. [EAN/PNS guideline](https://onlinelibrary.wiley.com/doi/10.1111/jns.12594)", "layers": [ { "id": "treatment-eligibility", "name": "Treatment eligibility", "description": "Represent the information needed for a responsible clinician to select or defer treatment.", "findings": [ { "id": "immunotherapy-decision", "name": "Immunotherapy decision", "description": "Record the indication, selected option and reason for the decision.", "questions": [ { "text": "How do onset timing, walking ability and current progression inform IVIg or plasma-exchange consideration?", "kind": "action", "id": "immunotherapy-decision-q01" }, { "text": "Which contraindications, patient preferences and service constraints influenced the clinician's decision?", "kind": "provenance", "id": "immunotherapy-decision-q02" }, { "text": "Which guideline version and patient-population assumptions support that decision?", "kind": "provenance", "id": "immunotherapy-decision-q03" } ] } ] }, { "id": "delivered-course-and-reassessment", "name": "Delivered course and reassessment", "description": "Distinguish prescribed treatment from delivered treatment and subsequent course.", "findings": [ { "id": "course-completion-and-effects", "name": "Course completion and effects", "description": "Link treatment delivery, interruptions and adverse events to serial assessments.", "questions": [ { "text": "What treatment was actually delivered, on which dates, and with what interruptions or adverse events?", "kind": "provenance", "id": "course-completion-and-effects-q01" }, { "text": "What objective changes followed treatment, and what prevents attributing those changes to treatment alone?", "kind": "measurement", "id": "course-completion-and-effects-q02" } ] }, { "id": "post-treatment-deterioration", "name": "Post-treatment deterioration", "description": "Represent renewed worsening without assuming that additional immunotherapy is appropriate.", "questions": [ { "text": "Did deterioration follow documented improvement or stabilization, and at what intervals from onset and treatment?", "kind": "measurement", "id": "post-treatment-deterioration-q01" }, { "text": "What specialist review is needed to distinguish ongoing progression, treatment-related fluctuation, complication or another diagnosis?", "kind": "action", "id": "post-treatment-deterioration-q02" } ] } ] } ] }, { "id": "recovery-and-longitudinal-revision", "name": "Recovery and longitudinal revision", "description": "Follow residual impairment, recovery goals and evidence that changes the episode interpretation.", "rationale": "Recovery assessment must include persistent weakness, pain and fatigue as well as return of independence. [NINDS overview](https://www.ninds.nih.gov/health-information/disorders/guillain-barre-syndrome)", "layers": [ { "id": "residual-burden-and-rehabilitation", "name": "Residual burden and rehabilitation", "description": "Connect persisting symptoms and limitations to practical recovery planning.", "findings": [ { "id": "recovery-profile", "name": "Recovery profile", "description": "Record neurological recovery and patient-experienced limitations separately.", "questions": [ { "text": "Which weakness, sensory symptoms, pain, fatigue or autonomic problems persist at each follow-up?", "kind": "measurement", "id": "recovery-profile-q01" }, { "text": "How do those problems affect self-care, mobility, communication, work or education compared with baseline?", "kind": "measurement", "id": "recovery-profile-q02" } ] }, { "id": "rehabilitation-goals", "name": "Rehabilitation goals", "description": "Link the current recovery profile to agreed support and reassessment.", "questions": [ { "text": "Which rehabilitation goals and supports have the patient and clinical team agreed?", "kind": "action", "id": "rehabilitation-goals-q01" }, { "text": "What observations will justify increasing, modifying or reducing support?", "kind": "action", "id": "rehabilitation-goals-q02" } ] } ] }, { "id": "prognosis-and-diagnostic-revision", "name": "Prognosis and diagnostic revision", "description": "Preserve uncertainty in forecasts and reconsider the diagnosis when longitudinal evidence warrants it.", "findings": [ { "id": "qualified-prognosis", "name": "Qualified prognosis", "description": "Record predictions with their inputs, intended outcome and applicability limits.", "questions": [ { "text": "If a prognostic score is used, which version, input dates and outcome horizon produced the estimate?", "kind": "provenance", "id": "qualified-prognosis-q01" }, { "text": "Does its validation population match this patient's age, phenotype and care setting?", "kind": "boundary", "id": "qualified-prognosis-q02" } ] }, { "id": "episode-reclassification", "name": "Episode reclassification", "description": "Keep the original assessment and the reasons for any later revision traceable.", "questions": [ { "text": "Does the duration or pattern of renewed worsening require review for acute-onset CIDP, recurrent GBS or another explanation?", "kind": "boundary", "id": "episode-reclassification-q01" }, { "text": "Who authorized a revised diagnosis, on what evidence, and which treatment or follow-up decisions changed?", "kind": "provenance", "id": "episode-reclassification-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)", "Acute motor axonal neuropathy (AMAN)", "Acute motor-sensory axonal neuropathy (AMSAN)", "Miller Fisher syndrome (MFS)", "Bickerstaff brainstem encephalitis (BBE)", "Pharyngeal-cervical-brachial (PCB) variant", "Paraparetic GBS", "Acute pandysautonomia" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of Guillain-Barré syndrome this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which versioned diagnostic framework should govern this model, and how should it represent variants that do not satisfy typical motor-sensory criteria?", "Which respiratory and autonomic escalation rules are validated for children, atypical phenotypes and settings with limited monitoring?", "What evidence should govern immunotherapy decisions in ambulant, late-presenting or variant cases?", "How should treatment-related fluctuation, recurrent GBS and acute-onset CIDP be distinguished when onset dates or serial examinations are incomplete?", "Which prognostic tools and patient-reported recovery measures remain valid across the populations and languages this catalogue must support?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 19, "questions": 39 } }, "draft": { "generator": "vr.draft.v3", "status": "draft-generated", "researched": false, "archetype": "disease or condition", "method": "Written from the archetype playbook - what this kind of thing needs beyond identity and provenance - and from the structure that recurred across 6,333 models already researched by two engines. Applied to this entry by rule. No source was read for this thing and no claim here is researched. This entry carries no facets of its own, so they were inferred from its domain - a guess about a whole domain applied to one thing.", "facetsInferred": true, "nextPass": "A researcher replaces this draft with a sourced specification. Treat every sentence below as a proposal to argue with.", "purpose": "Give an agent a durable, checkable way to recognise a Guillain–Barré syndrome, record what state it is in, and decide what may be done with it.", "whatItIs": "Enable an AI agent to represent Guillain-Barré syndrome, assess evidence and episode severity, and identify appropriate clinical review, escalation and follow-up actions.", "characteristics": { "substance": "information", "origin": "conceptual", "agency": "inert" }, "whatYouCanDoWithIt": [ "read and interpreted" ], "distinguishingFeatures": [ "Names folded into this entry, which a task may need to split apart again: acute motor axonal neuropathy, acute motor and sensory axonal neuropathy, variant of Guillain-Barre syndrome.", "3 finer distinctions are held as aliases rather than separate entries, because telling them apart needs a task that asks for it.", "Described in 64 Wikipedia languages, which is a measure of how widely the thing is known, not of how important it is." ], "openQuestionsForResearch": [ "Which of the bundles below does a real task actually need, and which are ceremony?", "What does this thing have that the facets do not capture at all?", "Which neighbouring kind is most often confused with a Guillain–Barré syndrome, and on what evidence are they told apart?" ], "whatItIsMadeOf": "content that has to be carried by something else", "physicalCharacter": [ "Does nothing on its own; everything it does, something else did to it.", "These come from the domain this entry sits in rather than from the entry itself, so treat them as a first guess about the whole domain applied to one thing." ], "whatCanBeDoneWithIt": [ "read it and act on what it says" ], "howItIsRecognised": [ "Recognised by criteria applied to signs and findings, not by appearance. Two conditions can look identical and be distinguished only by test." ], "relatedModels": [ { "relation": "covers", "note": "Finer kinds folded into this entry because telling them apart needs a task that asks for it. Each is a model waiting to be split out when one does.", "targets": [ "acute motor axonal neuropathy", "acute motor and sensory axonal neuropathy", "variant of Guillain-Barre syndrome" ] } ], "standing": "Described in 64 Wikipedia languages, which measures how widely it is written about rather than how important or how common it is. 3 finer distinctions are held inside this entry as names rather than as separate models.", "structure": { "bundles": [ { "id": "identity-and-classification", "name": "Identity, naming and classification", "description": "How an agent tells one Guillain–Barré syndrome from another, and a Guillain–Barré syndrome from things that resemble it.", "rationale": "Recognition comes before every other claim. Without stable identity nothing else in the model can be trusted to be about the same thing twice.", "layers": [ { "id": "naming-and-identifiers", "name": "Names and identifiers", "description": "The names this thing goes by and the identifiers that survive translation and time.", "findings": [ { "id": "preferred-name-and-aliases", "name": "Preferred name, aliases and local names", "description": "Which name to use, which names mean the same thing, and which merely sound similar.", "questions": [ { "id": "preferred-name-and-aliases-q01", "text": "What identifies and describes the name of a Guillain–Barré syndrome, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "preferred-name-and-aliases-q02", "text": "Who or what asserted this about the name of a Guillain–Barré syndrome, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "preferred-name-and-aliases-q03", "text": "What may an agent decide or do once the name of a Guillain–Barré syndrome is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "stable-identifiers", "name": "Stable identifiers and external keys", "description": "Identifiers that keep pointing at this kind of thing across systems and languages.", "questions": [ { "id": "stable-identifiers-q01", "text": "What identifies and describes an identifier for a Guillain–Barré syndrome, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stable-identifiers-q02", "text": "Who or what asserted this about an identifier for a Guillain–Barré syndrome, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stable-identifiers-q03", "text": "What may an agent decide or do once an identifier for a Guillain–Barré syndrome is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "classification-and-granularity", "name": "Classification and granularity", "description": "Where a Guillain–Barré syndrome sits among kinds, and how finely a task needs to cut it.", "findings": [ { "id": "kind-and-parents", "name": "Kind, parents and neighbouring kinds", "description": "The classes this thing belongs to and the ones it is next to.", "questions": [ { "id": "kind-and-parents-q01", "text": "What identifies and describes the kind of a Guillain–Barré syndrome, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "kind-and-parents-q02", "text": "Who or what asserted this about the kind of a Guillain–Barré syndrome, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "kind-and-parents-q03", "text": "What may an agent decide or do once the kind of a Guillain–Barré syndrome is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "distinguishing-features", "name": "Distinguishing features", "description": "What separates a Guillain–Barré syndrome from the things most often confused with it.", "questions": [ { "id": "distinguishing-features-q01", "text": "What identifies and describes what distinguishes a Guillain–Barré syndrome, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "distinguishing-features-q02", "text": "Who or what asserted this about what distinguishes a Guillain–Barré syndrome, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "distinguishing-features-q03", "text": "What may an agent decide or do once what distinguishes a Guillain–Barré syndrome is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "state-and-lifecycle", "name": "State and lifecycle", "description": "The states a Guillain–Barré syndrome passes through and the events that move it between them.", "rationale": "Most decisions about a thing depend on what state it is in now, which is a claim with a time on it, not a property.", "layers": [ { "id": "lifecycle-stages", "name": "Lifecycle stages", "description": "From coming into existence to ceasing to be one of these.", "findings": [ { "id": "stages-and-transitions", "name": "Stages and transitions", "description": "The stages worth naming and what moves a Guillain–Barré syndrome between them.", "questions": [ { "id": "stages-and-transitions-q01", "text": "What identifies and describes the lifecycle of a Guillain–Barré syndrome, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stages-and-transitions-q02", "text": "Who or what asserted this about the lifecycle of a Guillain–Barré syndrome, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stages-and-transitions-q03", "text": "What may an agent decide or do once the lifecycle of a Guillain–Barré syndrome is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "observations-and-status", "name": "Observations and current status", "description": "What is observed about a Guillain–Barré syndrome, how often and by whom.", "findings": [ { "id": "observation-record", "name": "Observation record", "description": "How an observation of a Guillain–Barré syndrome is recorded so that it can be superseded rather than overwritten.", "questions": [ { "id": "observation-record-q01", "text": "What identifies and describes an observation of a Guillain–Barré syndrome, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "observation-record-q02", "text": "Who or what asserted this about an observation of a Guillain–Barré syndrome, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "observation-record-q03", "text": "What may an agent decide or do once an observation of a Guillain–Barré syndrome is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "content-and-access", "name": "Content, encoding and access", "description": "What a Guillain–Barré syndrome says, how it is encoded and who may read it.", "rationale": "An informational thing carries content that can be copied, versioned and withheld, none of which its physical carrier explains.", "layers": [ { "id": "content-and-encoding", "name": "Content and encoding", "description": "The content itself, its format and its language.", "findings": [ { "id": "content-and-format", "name": "Content, format and language", "description": "What a Guillain–Barré syndrome contains and in what form it is held.", "questions": [ { "id": "content-and-format-q01", "text": "What identifies and describes the content of a Guillain–Barré syndrome, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "content-and-format-q02", "text": "Who or what asserted this about the content of a Guillain–Barré syndrome, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "content-and-format-q03", "text": "What may an agent decide or do once the content of a Guillain–Barré syndrome is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "access-and-rights", "name": "Access, rights and retention", "description": "Who may read, copy or change it, and for how long it is kept.", "findings": [ { "id": "access-rules", "name": "Access rules and retention", "description": "The permissions attached to a Guillain–Barré syndrome and the period it survives.", "questions": [ { "id": "access-rules-q01", "text": "What identifies and describes access to a Guillain–Barré syndrome, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "access-rules-q02", "text": "Who or what asserted this about access to a Guillain–Barré syndrome, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "access-rules-q03", "text": "What may an agent decide or do once access to a Guillain–Barré syndrome is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "diagnosis-and-criteria", "name": "Diagnosis, criteria and coding", "description": "What makes a case of Guillain–Barré syndrome a case, and under which revision.", "rationale": "Criteria change between revisions, so a diagnosis without its coding revision cannot be compared with a later one.", "layers": [ { "id": "criteria", "name": "Diagnostic criteria", "description": "The criteria in force and who issues them.", "findings": [ { "id": "criteria-record", "name": "Criteria, issuer and revision", "description": "What must be true for a diagnosis, according to whom.", "questions": [ { "id": "criteria-record-q01", "text": "What criteria define Guillain–Barré syndrome, issued by which body, in which revision?", "kind": "definition" }, { "id": "criteria-record-q02", "text": "What changed between revisions that would reclassify existing cases?", "kind": "boundary" } ] } ] }, { "id": "coding", "name": "Coding and terminology", "description": "The codes used to record it and their mapping.", "findings": [ { "id": "coding-record", "name": "Codes and mappings", "description": "Which classification codes apply and how they map.", "questions": [ { "id": "coding-record-q01", "text": "Which classification and terminology codes cover Guillain–Barré syndrome, and how do they map to each other?", "kind": "definition" }, { "id": "coding-record-q02", "text": "What is lost when a case is mapped from one scheme to another?", "kind": "boundary" } ] } ] } ] }, { "id": "course-and-population", "name": "Course, population and care", "description": "How Guillain–Barré syndrome develops, whom it affects, and what is done about it.", "rationale": "The condition, the diagnosis and the episode of care are three different things, and an agent must not merge them.", "layers": [ { "id": "course", "name": "Course and stages", "description": "Onset, progression, remission and outcome.", "findings": [ { "id": "course-record", "name": "Stages and transitions", "description": "The stages recorded and what moves a case between them.", "questions": [ { "id": "course-record-q01", "text": "What course does Guillain–Barré syndrome typically take, and what marks each stage?", "kind": "definition" }, { "id": "course-record-q02", "text": "What separates the condition itself from an episode of care for it?", "kind": "boundary" } ] } ] }, { "id": "population", "name": "Affected populations", "description": "Who is affected, how often, and on what evidence.", "findings": [ { "id": "epidemiology", "name": "Prevalence and its basis", "description": "Rates with their population, period and source.", "questions": [ { "id": "epidemiology-q01", "text": "What prevalence or incidence is reported for Guillain–Barré syndrome, in which population and period?", "kind": "measurement" }, { "id": "epidemiology-q02", "text": "What may an agent not conclude about an individual from a population rate?", "kind": "action" } ] } ] } ] }, { "id": "provenance-and-evidence", "name": "Provenance, evidence and time", "description": "Where every claim about a Guillain–Barré syndrome came from and when it held.", "rationale": "A claim without a source and a time cannot be superseded, only overwritten, and an agent that overwrites loses the ability to explain itself.", "layers": [ { "id": "source-and-authority", "name": "Source and authority", "description": "Who said it, on what evidence, and how strongly.", "findings": [ { "id": "claim-provenance", "name": "Claim provenance and confidence", "description": "The authority behind each claim about a Guillain–Barré syndrome and how confident it is.", "questions": [ { "id": "claim-provenance-q01", "text": "What identifies and describes a claim about a Guillain–Barré syndrome, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "claim-provenance-q02", "text": "Who or what asserted this about a claim about a Guillain–Barré syndrome, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "claim-provenance-q03", "text": "What may an agent decide or do once a claim about a Guillain–Barré syndrome is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "time-and-versions", "name": "Time, versions and supersession", "description": "When a claim was true, when it was learnt, and what replaced it.", "findings": [ { "id": "validity-and-supersession", "name": "Validity period and supersession", "description": "How an old claim about a Guillain–Barré syndrome is retired without being erased.", "questions": [ { "id": "validity-and-supersession-q01", "text": "What identifies and describes the validity of a claim about a Guillain–Barré syndrome, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "validity-and-supersession-q02", "text": "Who or what asserted this about the validity of a claim about a Guillain–Barré syndrome, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "validity-and-supersession-q03", "text": "What may an agent decide or do once the validity of a claim about a Guillain–Barré syndrome is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] } ] }, "statistics": { "bundles": 6, "layers": 12, "findings": 14, "questions": 38 } } } }